Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

M.C.T. van Zeijl, J.B.A.G. Haanen, M.W.J.M. Wouters, L.C. de Wreede, A. Jochems, M.J.B. Aarts, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E.W. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, K.J.M. van der Hoeven, A.J.M. van den Eertwegh

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)256-264
Number of pages9
JournalJournal of Immunotherapy
Volume43
Issue number8
DOIs
Publication statusPublished - 1 Oct 2020

Keywords

  • anti-pd-1 antibody
  • anti-pd-1 therapy
  • brain metastases
  • combined nivolumab
  • competing risks
  • immunotherapy
  • ipilimumab
  • lactate-dehydrogenase
  • metastatic melanoma
  • multicenter
  • nivolumab
  • open-label
  • pembrolizumab
  • population-based
  • real-world
  • survival
  • LACTATE-DEHYDROGENASE
  • SURVIVAL
  • anti-PD-1 antibody
  • METASTATIC MELANOMA
  • BRAIN METASTASES
  • anti-PD-1 therapy
  • MULTICENTER
  • COMBINED NIVOLUMAB
  • OPEN-LABEL
  • PEMBROLIZUMAB
  • IMMUNOTHERAPY
  • IPILIMUMAB

Cite this